This breakthrough designation - only for relapsed/refractory 17p deletion patients should mean the path to FDA approval will be smooth and short in the USA. This is very good news for my fellow American patients with 17p del. Hope the rest of the world stays in step.
We are only going to beat this cancer by giving it no backdoor escape routes and combos of non-chemo targeted therapies are already rolling out.
I am excited.
For the details, the official press release, and the background on the FDA breakthrough designation, visit our website cllsociety.org (under the news section).
We are all in this together.